<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-0108</journal-id>
<journal-title><![CDATA[Revista Española de Enfermedades Digestivas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. esp. enferm. dig.]]></abbrev-journal-title>
<issn>1130-0108</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Patología Digestiva]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-01082009001100001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Infection with Helicobacter pylori: Prevalence, research and impact of antibiotic resistance]]></article-title>
<article-title xml:lang="es"><![CDATA[Infección por Helicobacter pylori: Prevalencia, investigación y repercusión de la resistencia antibiótica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro-Fernández]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Romero]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Universitario de Valme Unit of Clinical Management of Digestives Diseases ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital Universitario de Valme Unit of Clinical Management of Microbiology ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>11</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>11</month>
<year>2009</year>
</pub-date>
<volume>101</volume>
<numero>11</numero>
<fpage>743</fpage>
<lpage>775</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-01082009001100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-01082009001100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-01082009001100001&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><body><![CDATA[ <p><font face="Verdana" size="2"><b>EDITORIAL</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="4"><b>Infection with <i>Helicobacter pylori</i>. Prevalence, research and impact of antibiotic resistance</b></font></p>     <p><font face="Verdana" size="4"><b>Infecci&oacute;n por <i>Helicobacter pylori</i>. Prevalencia, investigaci&oacute;n y repercusi&oacute;n de la resistencia antibi&oacute;tica</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>M. Castro-Fernández and J. Vargas-Romero<sup>1</sup></b></font></p>     <p><font face="Verdana" size="2">Unit of Clinical Management of Digestives Diseases and <sup>1</sup>Clinical Management of Microbiology. CIBERehd. Hospital Universitario de Valme. Sevilla, Spain</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">Antibiotic resistance is probably the primary cause of failed therapy for infectious disease, particularly for infection with <i>Helicobacter pylori</i>. Since the relevance of infection with <i>H. pylori</i> in the pathogenesis of peptic gastroduodenal disease and gastric neoplasms was unveiled, the effectiveness of treatment with a number of antibiotics and therapeutic schemes has been investigated (1). <i>H. pylori</i> is intrinsically resistant to glycopeptides, cefsulodin, polymyxines, nalidixic acid, trimetoprim, sulfonamides, nystatin, amphotericin B, and cycloheximide, whereas wild-type strains are susceptible to &beta;-lactams (except cefsulodin), phosphomycin, macrolides, aminoglycosides, tetracyclines, chloramphenicol, rifampicin, fluoroquinolones, 5-nitroimidazoles, and nitrofurans (2). So-called quadruple therapy with a proton-pump inhibitor (PPI) in combination with bismuth, tetracyclines and metronidazole, and most particularly triple therapy with a PPI associated with clarithromycin and amoxicillin or metronidazole represent the most widely accepted therapies. The European Helicobacter Study Group (EHSG) reported in 1997 the conclusions of the 1<sup>st</sup> Consensus Conference held in Maastricht, and recommended triple therapy as first-line treatment for infection with <i>H. pylori</i>, with quadruple therapy being held in reserve for potential first-line treatment failures (3). Triple therapy has remained the first-choice regimen during the past decade, and has been recommended by most consensus meetings and both European and American scientific societies (4-8). The initial effectiveness of this regimen, around 80-90%, has progressively declined to below 80-70% in the last few years, which has led to consider novel therapeutic approaches (9-19). Acquired resistance to commonly-used antibiotics, particularly clarithromycin and metronidazole, is thought to be the primary cause of treatment failure, but other causes such as non-compliance or prescriptions with inadequate dosage or duration should also be taken into account (20-22).</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Prevalence of antibiotic resistance of <i>H. pylori</i></b></font></p>     <p><font face="Verdana" size="2">During the period 1999-2003 multiple studies were reported on the prevalence of primary antibiotic resistance in <i>H. pylori</i>, and significant variations were seen among countries or even regions and ethnic groups within countries. In Europe, a low prevalence of resistance to clarithromycin was reported in the Netherlands, Germany, and Sweden (1.7-2.9%), which was higher in Spain, France and Portugal (12-22%) (22-27). Interestingly, prevalence in northern Italy was 1.8 <i>versus</i> 23.4% in central Italy (28-29). It was 10-12% in the United States, 25% in Mexico, in 9.8% in Brazil, 11-13% in Japan, and 5-6% in Korea (30-37). The prevalence of resistance to metronidazole was 15-40% in Europe, 20-35% in the United States, 76% in Mexico, 53% in Brazil, 9-12% in Japan and 40% in Korea, while that of resistance to amoxicillin and tetracyclines was below 1% (22-37). A meta-analysis of 20 clinical trials in the USA acknowledges an increased prevalence of resistance to clarithromycin, from 4.9% in 1993-95 to 10.1% in 1995-99 (38). A multicenter European study with homogeneous methodology performed in 22 countries during 1998 found that the prevalence of primary resistance to clarithromycin was 9.9%, to metronidazole was 33.1%, and to amoxicillin was 0.8%. Resistance to clarithromycin was more common in children <i>versus</i> adults, and in southern (18%) <i>versus</i> central (9.3%) or northern (4.2%) European countries. Simultaneous resistance to clarithromycin and metronidazole was also more frequent in southern European countries (39).</font></p>     <p><font face="Verdana" size="2">A multicenter European study was carried out in 14 countries during 1999-2002 to assess <i>H. pylori</i> antibiotic resistance in the pediatric population. The prevalence of primary resistance to clarithromycin was 20%, higher in younger children (&lt; 6 vs. &gt; 12 years) and in people residing in southern Europe; that of primary resistance to metronidazole was 23%, to both clarithromycin and metronidazole was 5.3%, and to amoxicillin was 0.6% (40).</font></p>     <p><font face="Verdana" size="2">In Spain several studies on the primary antibiotic resistance of <i>H. pylori</i> were published during 1999-2004, which revealed that the prevalence of resistance to clarithromycin ranged from 8.7 to 13%, and to metronidazole from 13.8 to 42% (26,41-44). In Seville, in our healthcare area, we observed that the prevalence of resistance to clarithromycin was 10%, and to metronidazole was 28.6%, during the period 1996-1998, consistent with previously reported data (45).</font></p>     <p><font face="Verdana" size="2">More recent publications (2006-09) show that, in the last decade, primary resistance to clarithromycin has either remained stable or increased, which would account for the progressively decreased effectiveness of triple therapy. Zullo et al., during 2004-06, identified in Italy a prevalence of primary resistance to clarithromycin of 16.9%, more common in patients with non-ulcer dyspepsia (19.1%) (46). Boyanova et al., in Bulgaria, observed a prevalence of primary resistance to clarithromycin of 10% during the period 1996-99, and of 17.9% during the period 2005-07 (47), and such an increase was also seen in other studies in Great Britain, Korea and Japan (48-50). Storskurubb et al., in Sweden, saw a low prevalence of primary resistance to clarithromycin (1.5%) and metronidazole (16.2%), which they relate to low use because of restrictive antibiotic policies (51). Aboderin et al. reported the opposite in Nigeria upon detection of 100% resistance to clarithromycin, ampicillin, and metronidazole in 32 study cases, which they related to uncontrolled use of these antibiotics (52). Agudo et al., in Madrid (Spain), during the period 2002-06, identified in children a high primary and secondary resistance to clarithromycin (49.2 and 70.6%), superior to that seen with metronidazole (32.8 and 41.2%), and dual resistance to clarithromycin and metronidazole, both primary and secondary, in 15.4 and 26.5% of cases, respectively; the authors highlighted the huge negative effect of such a high prevalence on the efficacy of triple therapy for <i>H. pylori</i> eradication (53). Kalach, during 1999-2005 in France, also detected in children a high prevalence of primary resistance to clarithromycin (23.2%), lower than that seen in Spain and that remained stable since 1994-98 (22.1%) (54). Antibiotic resistance and its negative influence on the effectiveness of eradicating therapies for <i>H. pylori</i> was a most relevant topic at the Third Maastricht Consensus Conference (6). Increased resistance to clarithromycin was endorsed in association with a greater use, and triple therapy with a PPI, amoxicillin or metronidazole, and clarithromycin was recommended for populations with resistance prevalence lower than 15-20%, whereas clarithromycin should otherwise be withheld. Quadruple therapy with a PPI, bismuth, tetracyclines and metronidazole may be an alternative to triple therapy as first-line regimen. The impact on triple therapy effectiveness is higher in cases with resistance to clarithromycin versus resistance to metronidazole (21,55). In the review by Megraud, published in 2004 (21), the effectiveness of triple therapy with a PPI, amoxicillin and clarithromycin is seen to decrease from 87.8 to 18.3% depending on sensitivity or resistance to the latter antibiotic, with a loss of efficacy at virtually 70%. That study also revealed that the efficacy of triple therapy with a PPI, amoxicillin and metronidazole, depending on the presence of susceptibility or resistance to the latter antimicrobial, has decreased from 89.4 to 64.4%, with a loss of efficacy at 25%, and that the effectiveness of triple therapy with a PPI, clarithromycin and metronidazole has decrease from 97 to 0%, according to susceptibility or resistance to both antibiotics, with an efficacy of 72.6% in case of clarithromycin susceptibility and metronidazole resistance, and of 50% in the opposite situation. It is thought that treatment for <i>H. pylori</i> infection should be recommended when efficacy is higher than 80% (intention-to-treat) or 85% (per protocol) (3,11,56). The current effectiveness of triple therapy as first-choice regimen is usually below 80%, even 70% in some studies (9-12), and cannot be therefore recommended.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Mechanisms of antibiotic resistance in <i>H. pylori</i></b></font></p>     <p><font face="Verdana" size="2">Evidence suggests that the mechanisms of antimicrobial resistance in <i>H. pylori</i> mainly result from chromosomal mutations (22,57) primarily acquired through vertical transmission among bacteria. Chromosomal mutations will show up in the offspring, which will consequently lead to a progressive increase in the prevalence of antimicrobial resistance. Horizontal transference from a resistant to a susceptible strain, both of them in the stomach, cannot be ruled out.</font></p>     <p><font face="Verdana" size="2">Clarithromycin is a bacteriostatic antibiotic; a semisynthetic derivative of erythromycin, it belongs in the macrolide class, and is the most powerful drug against <i>H. pylori</i>. It targets ribosomes, thereby blocking bacterial protein synthesis. Resistance to clarithromycin results from point mutations that occur in the 23S rRNA gene and modify ribosome structure, impairing antibiotic binding. Most common mutations include adenine replacement by cytosine or guanine at position 2142 (A2142C, A2142G), or by guanine at position 2143 (A2143G); A2115G and G2141A occur less commonly. These mutations enable resistant strains to tolerate increasing antibiotic concentrations, from 1 to 64 mg/mL (58,59).</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Amoxicillin is a bactericidal antibiotic inhibiting bacterial wall synthesis. The prevalence of <i>H. pylori</i> resistance to amoxicillin is very low, and this antibiotic requires the presence of penicillin-binding proteins (PBPs) for proper functioning. The mechanism of resistance generated by <i>H. pylori</i> consists of mutations in gene pbp that result in changed PBPs with greater antibiotic affinity. Resistant strains do not generate amoxicillin-PBP complexes, and thus preclude bactericidal effects (57).</font></p>     <p><font face="Verdana" size="2">Tetracyclines are bacteriostatic antibiotics that target ribosomes to block bacterial protein synthesis. The prevalence of resistance to tetracyclines in <i>H. pylori</i> is very low, and is acquired via mutations in the 16S rRNA gene, primarily in adenine-guanine-adenine triplets at positions 926 to 928 (AGA 926-928); single, dual or even triple substitutions may occur. A triple replacement of AGA926-928 by thymine, thymine and cytosine, respectively (AGA926-928&rarr;TTC), in the 16S rRNA gene enables strains to tolerate antibiotic concentrations up to 64 mg/mL; dual mutations allow the tolerance of concentrations up to 8 mg/mL, and single replacements enable tolerance to 2 mg/mL (60,61). The presence of other potential mechanisms of resistance has been discussed in recent years, involving either TetA efflux protein (62) or the presence of a membrane permeability inhibitor.</font></p>     <p><font face="Verdana" size="2">Metronidazole is a bactericidal antibiotic within the nitroimidazole class that has been widely and indiscrimanetely used in the management of multiple infections, thus conditioning a high prevalence of resistance in <i>H. pylori</i>. Nitroimidazoles, on entering target cells, are activated via a reduction process mediated by the enzyme NADPH-nitroreductase, which damages DNA and bacterial structures. The mechanisms of resistance currently known are based on mutations in genes <i>rdxA</i> and <i>frxA</i>, which would block cell-related nitroimidazole activation.</font></p>     <p><font face="Verdana" size="2">Levofloxacin and ciprofloxacin are bactericidal antibiotics in the quinolone class; their mechanism of action is similar and consists of blocking bacterial DNA replication by binding the enzyme DNA-gyrase, coded for by genes gyrA and gyrB. <i>H. pylori</i> resistance to these antibiotics is conditioned by mutations in <i>gyrA</i> QRDR <i>(quinolone resistance-determining region)</i> (63).</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Methods for the study of <i>H. pylori</i> antibiotic susceptibility</b></font></p>     <p><font face="Verdana" size="2">Multiple methods are available for the study of <i>H. pylori</i> antibiotic susceptibility, which may be categorized as phenotypical methods, most commonly used and based on gastric biopsy cultures, including agar dilution and E-test (epsilometer test), and genotypical methods, including fluorescent in situ hybridation, PCR (polymerase chain reaction), both conventional and with sequencing, RFLP <i>(restriction fragment length polymorphism)</i> PCR, and real-time PCR, which allows to directly detect chromosomal mutations in gastric biopsies and feces. The Clinical and Laboratory Standards Institute (CLSI), formerly the National Committee for Clinical Laboratory Standards (NCCLS), recommends agar dilution as gold standard for the study of <i>H. pylori</i> susceptibility to antibiotics, specifically for minimum inhibitory concentration (MIC) estimates, and establishes cutoff points for clarithromycin (64). The British Society for Antimicrobial Chemotherapy (BSAC) recommends in turn E-test diffusion, which has a high correlation with agar dilution. E-test has the benefit of being a quantitative method with direct MIC expression; it also adapts to slow-growing bacteria such as <i>H. pylori</i> (65). Other available methods include broth dilution and disk diffusion (66,67). Cutoff points suggested for clarithromycin include: &le; 0.25 mg/mL for susceptible strains, &ge;1 mg/mL for resistant strains, and 0,5 mg/mL for intermediate strains. These cutoffs have allowed excellent predicting values for the success of triple therapy with a PPI, clarithromycin and amoxicillin. No standardized criteria are available for antibiotics, including amoxicillin, tetracyclines, rifabutin, and levofloxacin. However, agar dilution may be used, and literature-endorsed cutoff points are used (47,68). Metronidazole is special in that most studies have shown an absence of interlab and intralab reproducibility on unknown grounds (2). Absent correlation between <i>H. pylori</i> susceptibility and eradicating therapy outcomes should also be counted in. <i>H. pylori</i> strains with a high MIC may be eradicated, possibly due to a variable redox potential within the stomach. The cutoff point usually considered to define resistance to metronidazole is &ge; 8 mg/mL. EHSG, at the 3<sup>rd</sup> Maastricht Consensus Conference, discourages the use of metronidazole susceptibility tests in clinical practice for want of clinico-bacteriological correlation (6).</font></p>     <p><font face="Verdana" size="2">Genotypical methods are particularly used for the study of clarithromycin resistance, but may also be applied for other antibiotics. Chromosomal mutations responsible for antibiotic resistance may be easily detected with molecular testing based on fluorescent <i>in situ</i> hybridation (69) or genomic amplification, mainly using PCR-related techniques (22). The advantages of such molecular tests include a shorter time for results, and an excellent correlation with susceptibility as assessed using phenotypical methods. Their main shortcoming is that they require a molecular microbiology laboratory. The first genotypical method used was RFLP PCR. This test amplifies the region harboring mutations, and synthesized fragments are then treated with restriction endonucleases that recognize specific mutation-generated sites. The size of the resulting fragments indicates the presence or absence of a mutation (22). RFLP PCR is a simple method but uses conventional PCR, which delays results and requires amplicon manipulation because of contamination risks. PCR with subsequent amplified fragment sequencing has been used on gastric bacteria and biopsies to assess resistance to clarithromycin and quinolones. It may also be used for other antibiotics such as amoxicillin. The technique is somewhat complex but automation has allowed its development (22). Lastly, real-time PCR has been successfully used (22,70) to detect any mutations in the amplified region, and represents a relevant advance as results may be obtained within 2 hours. It has been used to directly identify <i>H. pylori</i> in biopsy and fecal samples, as well as in cultured bacteria. Real-time PCR for fecal samples has become a promising diagnostic technique as it represents a rapid, non-invasive method allowing direct bacterial identification and an assessment of clarithromycin susceptibility. A higher degree of standardization demands a commercially available kit with high sensitivity and specificity.</font></p>     <p><font face="Verdana" size="2">The study by Torres Debat et al. included in this issue of the <i>Spanish Journal of Gastroenterology</i> (71) is first to inform on the prevalence of <i>H. pylori</i> antibiotic resistance in Uruguay, and also investigates the molecular mechanisms of clarithromycin resistance using PCR. The authors research the prevalence of antibiotic resistance using the E-test in two time periods and two adult populations with gastric biopsy cultures positive for <i>H. pylori</i>, and diverse ethnic descent. In 2001 they studied 19 patients representative of the general population, and in 2006 they studied 31 patients of African descent. The prevalence of resistance to metronidazole was 36.8 and 35.5%, respectively; to clarithromycin, 0 and 19.4%; to levofloxacin, 5.2 and 3.2%; and to amoxicillin and tetracyclines, 0% for both groups. Of note is the variable prevalence of clarithromycin resistance in these two periods of time and/or population groups. The fact that antibiotic - and specifically clarithromycin - resistance prevalence varies among countries or among regions, social groups, or ethnic groups within one same country is well known. Information available on antibiotic resistance prevalence in African populations or Latin American countries is insufficient. In Mexico, during the years 1995-97, the prevalence reported for clarithromycin resistance was 25% (32); recently, a prevalence of 2% was acknowledged in Paraguay (72). Aboderin, during the period 2002-06 in Nigeria, detected a 100% prevalence of clarithromycin resistance, and that for other antibiotics was also very high (52). Available data are anyway inadequate for drawing conclusions. The prevalence of clarithromycin resistance found in 2006 by Torres Debat et al. in Uruguay is high, and these authors also state that whether this reflects the current status in the general population, with a rapid increase during the last few years, or the current status in a specific Uruguayan ethnic group is uncertain, the latter possibility being potentially supported by the finding of one single mutation at position 2143 in all cases (71). The high prevalence of resistance to metronidazole is similar to that currently seen in some developed rather than - as claimed by the authors - developing countries (39).</font></p>     <p><font face="Verdana" size="2">As previously stated, it is accepted that triple therapy should not be used to manage <i>H. pylori</i> infection when the prevalence of clarithromycin resistance is higher than 15-20%, as in the above study; in such cases other therapeutic alternatives should be considered. It would be desirable to have regularly updated, reliable information on the prevalence of antibiotic resistance in <i>H. pylori</i>, specifically regarding clarithromycin, for the various countries, regions or healthcare areas, so that the potentially most effective eradicating regimen could be assessed on an individual basis. The study of antibiotic resistance is particularly necessary when low effectiveness is found regarding triple therapy for <i>H. pylori</i> eradication, and in certain patients following the failure of an initial or second eradicating therapy.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>References</b></font></p>     <!-- ref --><p><font face="Verdana" size="2">1. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perpective. Helicobacter 2007; 12(Supl. 2): 50-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332478&pid=S1130-0108200900110000100001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">2. Lambert, T, Megraud F, Gerbaud G, Courvalin P. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother 1986; 30: 510-1.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332479&pid=S1130-0108200900110000100002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">3. The European Helicobacter pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997; 41: 8-13.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332480&pid=S1130-0108200900110000100003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">4. Mon&eacute;s J, Gisbert JP, Borda F, Dom&iacute;nguez-Mu&ntilde;oz E, y Grupo Conferencia Espa&ntilde;ola de Consenso sobre Helicobacter pylori. Indications, diagnostic test and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig 2005; 97: 348-74.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332481&pid=S1130-0108200900110000100004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">5. Gisbert JP, Calvet X, Gomoll&oacute;n F, Mon&eacute;s J, y Grupo Conferencia Espa&ntilde;ola de Consenso sobre Helicobacter pylori. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Espa&ntilde;ola de Consenso. Med Clin (Barc) 2005; 125: 301-16.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332482&pid=S1130-0108200900110000100005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al., The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332483&pid=S1130-0108200900110000100006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">7. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, et al., the Working Group of the Cervia II Meeting. "Cervia II Working Group Report 2006": Guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007; 39: 782-9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332484&pid=S1130-0108200900110000100007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">8. Chey WD, Wong BCY, and the Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guideline on the Management of the Helicobacter pylori Infection. Am J Gastroenterol 2007; 102: 1808-25.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332485&pid=S1130-0108200900110000100008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">9. Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008; 13(Supl. 1): 35-40.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332486&pid=S1130-0108200900110000100009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">10. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332487&pid=S1130-0108200900110000100010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">11. Graham DY, Lu H, Yamaoka. Therapy for Helicobacter pylori infection can be improved. Drugs 2008; 68: 725-36.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332488&pid=S1130-0108200900110000100011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">12. Boixeda D, Mart&iacute;n de Argila C, Bermejo F, L&oacute;pez San Rom&aacute;n A, Hern&aacute;ndez Ranz F, Grac&iacute;a Plaza A. seven-day protom pump inhibitor, amoxicillin and clarithromycin triole therapy. Factors that influence Helicobacter pylori eradication success. Rev Esp Enferm Dig 2003; 95: 202-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332489&pid=S1130-0108200900110000100012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">13. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP, HP Study Group ot the Asociaci&oacute;n Espa&ntilde;ola de Gastroenterolog&iacute;a. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005; 100: 1696-701.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332490&pid=S1130-0108200900110000100013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">14. Gisbert JP, Gonz&aacute;lez L, Calvet X, Garc&iacute;a N, L&oacute;pez, Roque M, et al. Protom pump inhibitor, clarithromycin an either amoxycillin or nitrimidazole. A meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332491&pid=S1130-0108200900110000100014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">15. Antos D, Schneider-Brachert W, B&auml;stlein E, H&auml;nel C, Haferland C, Buchner M, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with know antimicrobial sensitivity. Helicobacter 2006; 11: 39-45.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332492&pid=S1130-0108200900110000100015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">16. Nista E, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006; 101: 1985-90.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332493&pid=S1130-0108200900110000100016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">17. Gisbert JP, Fern&aacute;ndez-Bermejo M, Molina-Infante M, P&eacute;rez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodr&iacute;guez JM, et al. Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2009; 43(4): 384-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332494&pid=S1130-0108200900110000100017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">18. Castro-Fern&aacute;ndez M, Lamas E, P&eacute;rez-Pastor A, Pab&oacute;n M, Aparcero R, Vargas-Romero J et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 2009; 101: 395-402.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332495&pid=S1130-0108200900110000100018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">19. S&aacute;nchez Delgado J, Calvet X, Bujanda L, Gisbert JP, Tit&oacute; L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103: 2220-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332496&pid=S1130-0108200900110000100019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">20. Pajares Garc&iacute;a JM, Pajares-Villarroya R, Gisbert JP. Helicobacter pylori infection: antibiotic resistence. Rev Esp Enfer Dig 2007; 99: 63-70.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332497&pid=S1130-0108200900110000100020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">21. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332498&pid=S1130-0108200900110000100021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">22. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332499&pid=S1130-0108200900110000100022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">23. Debets-Ossenkopp YJ, Herscheid A, Pot RGJ, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CMJE. Prevalence of Helicobacter pylori resistance to metronidazol, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 43: 511-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332500&pid=S1130-0108200900110000100023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">24. Wolle K, Leodolter A, Malfertheimer P, K&ouml;nig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332501&pid=S1130-0108200900110000100024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">25. Megraud F, Lehn N, Lind T, Bayerd&ouml;rffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicentre trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332502&pid=S1130-0108200900110000100025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">26. Cuch&iacute; Burgos E, Forn&eacute; Bardera M, Quintana Riera S, Lite Lite J, Garau Alemany J. Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment. Enferm Infecc Microbiol Clin 2002; 20: 157-60.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332503&pid=S1130-0108200900110000100026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">27. Cabrita J, Oleastro M, Matos R, Mantente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332504&pid=S1130-0108200900110000100027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">28. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332505&pid=S1130-0108200900110000100028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">29. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 763-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332506&pid=S1130-0108200900110000100029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">30. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicentre , doubled-blind trials. Am J Gastroenterol 2000; 95: 3393-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332507&pid=S1130-0108200900110000100030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">31. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham, DY, et al. Pattern of primary resistance of Helicobacter pylori to metronidazol or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332508&pid=S1130-0108200900110000100031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">32. Torres J, Camorlinga-Ponce M, P&eacute;rez-P&eacute;rez G, Madrazo-de la Garza A, Dehesa M, Gonz&aacute;lez-Valencia G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39: 2677-80.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332509&pid=S1130-0108200900110000100032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">33. Prazeres Magalhaes P, de Magalhaaes Queiroz DM, Campos Barbosa DV, Aguilar Rocha G, Nogueira Mendes E, Santos A, et al. Helicobacter pylori primary resistance to metronidazol and clarithromycin in Brazil. Antimicrob Agents Chemother 2002; 46: 2021-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332510&pid=S1130-0108200900110000100033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">34. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332511&pid=S1130-0108200900110000100034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">35. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44: 2214-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332512&pid=S1130-0108200900110000100035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">36. Kim JJ, Reddy R, Lee M, Kim JM, Osato MS, Graham DY, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-61.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332513&pid=S1130-0108200900110000100036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">37. Eun CS, Han DS, Park JY, Jeon YC, Hahm JS, Kim KS, et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003; 38: 436-41.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332514&pid=S1130-0108200900110000100037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">38. Meyer JM, Silliman NP, Wang W, Siepman NY, Suggs JE, Morris D, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) STUDY, 1993-1999. Ann Intern Med 2002; 136: 13-24.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332515&pid=S1130-0108200900110000100038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">39. Glupczynski Y, Megraud F, L&oacute;pez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332516&pid=S1130-0108200900110000100039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">40. Koletzko S, Richy F, Bontems P, Crome J, Kalach N, Monteiro ML, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55: 1 711-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332517&pid=S1130-0108200900110000100040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">41. Rojas Feria M, Su&aacute;rez Barrenechea AI, Conejo Gonzalo C, Hergueta Delgado P, Romero Castro R, Herrer&iacute;as Guti&eacute;rrez JM. Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. Rev Esp Enferm Dig 2000; 92: 793-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332518&pid=S1130-0108200900110000100041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">42. Toro C, Garc&iacute;a-Samaniego J, Carb&oacute; J, I&ntilde;iguez A, Alarc&oacute;n T, L&oacute;pez-Brea M, et al. Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid. Rev Esp Quimioter 2001; 14: 172-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332519&pid=S1130-0108200900110000100042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">43. Ferrero M, Duc&oacute;ns JA, Sicilia B, Santolaria S, Sierra E, Gomoll&oacute;n F. Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. Int J Antimicrob Agents 2000; 16: 245-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332520&pid=S1130-0108200900110000100043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">44. Gomoll&oacute;n F, Santolaria S, Sicilia B, Ferrero M, Revillo MJ, Duc&oacute;ns J, et al. Resistencia de Helicobacter pylori al metronidazol y a la claritromicina: an&aacute;lisis descriptivo entre 1997 y 2000. Med Clin (Barc) 2004; 123: 481-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332521&pid=S1130-0108200900110000100044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">45. Garc&iacute;a D&iacute;az E, Romero G&oacute;mez M, Vargas J, Guil A, Bernal S, Castro M. Prevalence and clinical significance of antibiotic resistance in Helicobacter pylori. Rev Esp Enferm Dig 2000; 92: 656-60.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332522&pid=S1130-0108200900110000100045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">46. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007; 25: 1429-34.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332523&pid=S1130-0108200900110000100046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">47. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008; 60: 409-15.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332524&pid=S1130-0108200900110000100047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">48. Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Eur Surveill 2007; 12: E3-4.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332525&pid=S1130-0108200900110000100048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">49. Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, et al. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol 2007; 50: 356-62.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332526&pid=S1130-0108200900110000100049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">50. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332527&pid=S1130-0108200900110000100050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">51. Storskrubb T, Aro P, Ronkainen J, Wreiber KK, Nyhlin H, Bolling-Sternevald E, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a randon adult Swedish population. Helicobacter 2006; 11: 224-30.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332528&pid=S1130-0108200900110000100051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">52. Aboderin OA, Abdu AR, Odetoyin B, Oneke IN, Lawal OO, Ndububa DA, et al. Antibiotic resistance of Helicobacter pylori from patients in Ife-Ife, South-west, Nigeria. Afr Health Sci 2007; 7: 143-7.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332529&pid=S1130-0108200900110000100052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">53. Agudo S, Alarc&oacute;n T, Cibrelus L, Urruzuno P, Mart&iacute;nez MJ, L&oacute;pez-Brea M. High percentage of clarithromycin and metronidazole resistence in Helicobacter pylori isolates obtained from Spanish children. Rev Esp Quimioter 2009; 22: 88-92.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332530&pid=S1130-0108200900110000100053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">54. Kalach N, Serhal L, Asmar E, Campeotto F, Bergeret M, Dehecq E, et al. Helicobacter pylori primary resistant straints over 11 years in French children. Diagn Microbiol Infect Dis 2007; 59: 217-22.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332531&pid=S1130-0108200900110000100054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">55. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332532&pid=S1130-0108200900110000100055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">56. Graham DY, Lu H, Yamaoka Y. A report to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332533&pid=S1130-0108200900110000100056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">57. Gerrits MM, Van Vliet AHM, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6: 699-709.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332534&pid=S1130-0108200900110000100057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">58. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332535&pid=S1130-0108200900110000100058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">59. Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Megraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41: 2724-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332536&pid=S1130-0108200900110000100059&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">60. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002; 184: 2131-40.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332537&pid=S1130-0108200900110000100060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">61. Dailidiene D, Bertoli MT, Miciuleviciene J, Mukhopadhyay AK, Dailide G, Pascasio MA, et al. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother 2002; 46: 3940-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332538&pid=S1130-0108200900110000100061&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">62. Li Y, Dannelly HK. Inactivation of the putative tetracycline resistance gene HP1165 in Helicobacter pylori led to loss of inducible tetracycline resistance. Arch Microbiol 2006; 185: 255-62.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332539&pid=S1130-0108200900110000100062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">63. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332540&pid=S1130-0108200900110000100063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">64. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement M100-S19. Clinical and Laboratory Standard Institute, Wayne, Pennsylvania, USA, January 2009; 29: 91.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332541&pid=S1130-0108200900110000100064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">65. Glupczynski Y, Broutet N, Cantagrel A, Andersen LP, Alarc&oacute;n T, Lopez Brea M, et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-52.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332542&pid=S1130-0108200900110000100065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">66. Sisto F, Maddalena M, Russello G, Bonomi A, Dubini F. Antimicrobial susceptibility testing of Helicobacter pylori determined by microdilution method using a new medium. Curr Microbiol 2009; 58: 559-63.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332543&pid=S1130-0108200900110000100066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">67. Grignon B, Tankovic J, Megraud F, Glupczynski Y, Husson MO, Conroy MC, et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist 2002; 8: 61-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332544&pid=S1130-0108200900110000100067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">68. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000; 46: 121-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332545&pid=S1130-0108200900110000100068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">69. Vega AE, Alarc&oacute;n T, Domingo D, L&oacute;pez-Brea M. Detection of clarithromycin-resistant Helicobacter pylori in frozen gastric biopsies from pediatric patients by a commercially available fluorescent in situ hybridization. Diagn Microbiol Infect Dis 2007; 59(4): 421-3.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332546&pid=S1130-0108200900110000100069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">70. Oleastro M, Menard A, Santos A, Lamouliatte H, Monteiro L, Barthelemy P, et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41: 397-402.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332547&pid=S1130-0108200900110000100070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">71. Torres Debat ME, P&eacute;rez P&eacute;rez G, Olivares A, Fern&aacute;ndez L, Raisler K, Gonzalez N, et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistence in straints isolated from patients in Uruguay. Rev Esp Enferm Dig 2009; 101: 757-62.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332548&pid=S1130-0108200900110000100071&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="Verdana" size="2">72. Fari&ntilde;a N, Kasamatsu E, Samudio M, Mor&aacute;n M, Sanabria R, Laspina F. Antimicrobial susceptibility of H. pylori straints obtained from Paraguayan patients. Rev Med Chil 2007; 135: 1009-14.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5332549&pid=S1130-0108200900110000100072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pajares]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pajares]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Evolution of Helicobacter pylori therapy from a meta-analytical perpective]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2007</year>
<volume>12</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>50-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gerbaud]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Courvalin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1986</year>
<volume>30</volume>
<page-range>510-1</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>The European Helicobacter pylori Study Group (EHPSG)</collab>
<article-title xml:lang="en"><![CDATA[Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1997</year>
<volume>41</volume>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Borda]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Muñoz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<collab>Grupo Conferencia Española de Consenso sobre Helicobacter pylori</collab>
<article-title xml:lang="en"><![CDATA[Indications, diagnostic test and Helicobacter pylori eradication therapy: Recommendations by the 2nd Spanish Consensus Conference]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2005</year>
<volume>97</volume>
<page-range>348-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gomollón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Monés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>Grupo Conferencia Española de Consenso sobre Helicobacter pylori</collab>
<article-title xml:lang="es"><![CDATA[Tratamiento erradicador de Helicobacter pylori: Recomendaciones de la II Conferencia Española de Consenso]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2005</year>
<volume>125</volume>
<page-range>301-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O'Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bazzoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[El-Omar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<collab>The European Helicobacter Study Group (EHSG)</collab>
<article-title xml:lang="en"><![CDATA[Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2007</year>
<volume>56</volume>
<page-range>772-81</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caselli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zullo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maconi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parente]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Alvisi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Casetti]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<collab>the Working Group of the Cervia II Meeting</collab>
<article-title xml:lang="en"><![CDATA[Cervia II Working Group Report 2006: Guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2007</year>
<volume>39</volume>
<page-range>782-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chey]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[BCY]]></given-names>
</name>
</person-group>
<collab>the American College of Gastroenterology^dthe Practice Parameters Committee</collab>
<article-title xml:lang="en"><![CDATA[American College of Gastroenterology Guideline on the Management of the Helicobacter pylori Infection]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2007</year>
<volume>102</volume>
<page-range>1808-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egan]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marzio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[O'Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of Helicobacter pylori infection]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2008</year>
<volume>13</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>35-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vakil]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Eradication therapy for Helicobacter pylori]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2007</year>
<volume>133</volume>
<page-range>985-1001</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaoka]]></surname>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Therapy for Helicobacter pylori infection can be improved]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2008</year>
<volume>68</volume>
<page-range>725-36</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boixeda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martín de Argila]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[López San Román]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Ranz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gracía Plaza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[seven-day protom pump inhibitor, amoxicillin and clarithromycin triole therapy: Factors that influence Helicobacter pylori eradication success]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2003</year>
<volume>95</volume>
<page-range>202-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ducons]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bujanda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bory]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montserrat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<collab>Asociación Española de Gastroenterología^dHP Study Group</collab>
<article-title xml:lang="en"><![CDATA[Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2005</year>
<volume>100</volume>
<page-range>1696-701</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Roque M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Protom pump inhibitor, clarithromycin an either amoxycillin or nitrimidazole: A meta-analysis of eradication of Helicobacter pylori]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2000</year>
<volume>14</volume>
<page-range>1319-28</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider-Brachert]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bästlein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hänel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haferland]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Buchner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with know antimicrobial sensitivity]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2006</year>
<volume>11</volume>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nista]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Candelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zocco]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Cremonini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ojetti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Finizio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2006</year>
<volume>101</volume>
<page-range>1985-90</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Bermejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Infante]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Gallardo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto-Bermejo]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos-Rodríguez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[J Clin Gastroenterol]]></source>
<year>2009</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>384-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro-Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lamas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Pastor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pabón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aparcero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2009</year>
<volume>101</volume>
<page-range>395-402</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Bujanda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Titó]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2008</year>
<volume>103</volume>
<page-range>2220-3</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pajares García]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Pajares-Villarroya]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Helicobacter pylori infection: antibiotic resistence]]></article-title>
<source><![CDATA[Rev Esp Enfer Dig]]></source>
<year>2007</year>
<volume>99</volume>
<page-range>63-70</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[H. pylori antibiotic resistance: prevalence, importance, and advances in testing]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2004</year>
<volume>53</volume>
<page-range>1374-84</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lehours]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Helicobacter pylori detection and antimicrobial susceptibility testing]]></article-title>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>2007</year>
<volume>20</volume>
<page-range>280-322</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debets-Ossenkopp]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Herscheid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pot]]></surname>
<given-names><![CDATA[RGJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kusters]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Vandenbroucke-Grauls]]></surname>
<given-names><![CDATA[CMJE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of Helicobacter pylori resistance to metronidazol, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>1999</year>
<volume>43</volume>
<page-range>511-5</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Leodolter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Malfertheimer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[König]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000]]></article-title>
<source><![CDATA[J Med Microbiol]]></source>
<year>2002</year>
<volume>51</volume>
<page-range>705-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lehn]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lind]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bayerdörffer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[O'Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Spiller]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial susceptibility testing of Helicobacter pylori in a large multicentre trial: the MACH 2 study]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1999</year>
<volume>43</volume>
<page-range>2747-52</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuchí Burgos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Forné Bardera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana Riera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lite Lite]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garau Alemany]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>157-60</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrita]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oleastro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mantente]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cabral]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barros]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999)]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2000</year>
<volume>46</volume>
<page-range>1029-31</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toracchio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marzio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2003</year>
<volume>35</volume>
<page-range>541-5</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pilotto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rassu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leandro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Franceschi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Mario]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU Interdisciplinary Group for the Study of Ulcer]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2000</year>
<volume>32</volume>
<page-range>763-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fennerty]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Osato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sugg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Suchower]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Probst]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicentre , doubled-blind trials]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2000</year>
<volume>95</volume>
<page-range>3393-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osato]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Penland]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Malaty]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pattern of primary resistance of Helicobacter pylori to metronidazol or clarithromycin in the United States]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2001</year>
<volume>161</volume>
<page-range>1217-20</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Camorlinga-Ponce]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Pérez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Madrazo-de la Garza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dehesa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González-Valencia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2001</year>
<volume>39</volume>
<page-range>2677-80</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prazeres Magalhaes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[de Magalhaaes Queiroz]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Campos Barbosa]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Rocha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nogueira Mendes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Helicobacter pylori primary resistance to metronidazol and clarithromycin in Brazil]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2002</year>
<volume>46</volume>
<page-range>2021-3</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez Aldana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kawarasaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nagasako]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mizushima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2002</year>
<volume>7</volume>
<page-range>306-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Asaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kashima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2000</year>
<volume>44</volume>
<page-range>2214-6</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Osato]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2001</year>
<volume>47</volume>
<page-range>459-61</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eun]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Hahm]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases]]></article-title>
<source><![CDATA[J Gastroenterol]]></source>
<year>2003</year>
<volume>38</volume>
<page-range>436-41</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Silliman]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Siepman]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Suggs]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) STUDY, 1993-1999]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2002</year>
<volume>136</volume>
<page-range>13-24</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glupczynski]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[López-Brea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2001</year>
<volume>20</volume>
<page-range>820-3</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koletzko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Richy]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bontems]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Crome]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kalach]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2006</year>
<volume>55</volume>
<page-range>1 711-6</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas Feria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez Barrenechea]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Conejo Gonzalo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hergueta Delgado]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Romero Castro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Herrerías Gutiérrez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2000</year>
<volume>92</volume>
<page-range>793-8</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Samaniego]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carbó]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Iñiguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[López-Brea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]]></article-title>
<source><![CDATA[Rev Esp Quimioter]]></source>
<year>2001</year>
<volume>14</volume>
<page-range>172-6</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ducóns]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Sicilia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Santolaria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gomollón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2000</year>
<volume>16</volume>
<page-range>245-8</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomollón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Santolaria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sicilia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Revillo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ducóns]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Resistencia de Helicobacter pylori al metronidazol y a la claritromicina: análisis descriptivo entre 1997 y 2000]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2004</year>
<volume>123</volume>
<page-range>481-5</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Díaz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Romero Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and clinical significance of antibiotic resistance in Helicobacter pylori]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2000</year>
<volume>92</volume>
<page-range>656-60</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zullo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Saracino]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Morini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>1429-34</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyanova]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gergova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolov]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Davidkov]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kamburov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jelev]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2008</year>
<volume>60</volume>
<page-range>409-15</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Teare]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005)]]></article-title>
<source><![CDATA[Eur Surveill]]></source>
<year>2007</year>
<volume>12</volume>
<page-range>E3-4</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Eun]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease]]></article-title>
<source><![CDATA[Korean J Gastroenterol]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>356-62</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Azuma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2007</year>
<volume>45</volume>
<page-range>4006-10</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Storskrubb]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ronkainen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wreiber]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Nyhlin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bolling-Sternevald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial susceptibility of Helicobacter pylori strains in a randon adult Swedish population]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2006</year>
<volume>11</volume>
<page-range>224-30</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aboderin]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdu]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Odetoyin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Oneke]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Lawal]]></surname>
<given-names><![CDATA[OO]]></given-names>
</name>
<name>
<surname><![CDATA[Ndububa]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antibiotic resistance of Helicobacter pylori from patients in Ife-Ife, South-west, Nigeria]]></article-title>
<source><![CDATA[Afr Health Sci]]></source>
<year>2007</year>
<volume>7</volume>
<page-range>143-7</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agudo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cibrelus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Urruzuno]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[López-Brea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High percentage of clarithromycin and metronidazole resistence in Helicobacter pylori isolates obtained from Spanish children]]></article-title>
<source><![CDATA[Rev Esp Quimioter]]></source>
<year>2009</year>
<volume>22</volume>
<page-range>88-92</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalach]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Serhal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Asmar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Campeotto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bergeret]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dehecq]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Helicobacter pylori primary resistant straints over 11 years in French children]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2007</year>
<volume>59</volume>
<page-range>217-22</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fischbach]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2007</year>
<volume>26</volume>
<page-range>343-57</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A report to grade Helicobacter pylori therapy]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2007</year>
<volume>12</volume>
<page-range>275-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerrits]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Van Vliet]]></surname>
<given-names><![CDATA[AHM]]></given-names>
</name>
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kusters]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>699-709</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Versalovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shortridge]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kibler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Griffy]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flamm]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1996</year>
<volume>40</volume>
<page-range>477-80</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Occhialini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Urdaci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doucet-Populaire]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bebear]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lamouliatte]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1997</year>
<volume>41</volume>
<page-range>2724-8</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trieber]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline]]></article-title>
<source><![CDATA[J Bacteriol]]></source>
<year>2002</year>
<volume>184</volume>
<page-range>2131-40</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dailidiene]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertoli]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Miciuleviciene]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mukhopadhyay]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Dailide]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pascasio]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2002</year>
<volume>46</volume>
<page-range>3940-6</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dannelly]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inactivation of the putative tetracycline resistance gene HP1165 in Helicobacter pylori led to loss of inducible tetracycline resistance]]></article-title>
<source><![CDATA[Arch Microbiol]]></source>
<year>2006</year>
<volume>185</volume>
<page-range>255-62</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bogaerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Berhin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nizet]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Glupczynski]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2006</year>
<volume>11</volume>
<page-range>441-5</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="book">
<collab>Clinical and Laboratory Standard Institute</collab>
<source><![CDATA[Performance standards for antimicrobial susceptibility testing: Nineteenth informational supplement M100-S19]]></source>
<year>Janu</year>
<month>ar</month>
<day>y </day>
<volume>29</volume>
<page-range>91</page-range><publisher-loc><![CDATA[Wayne^ePennsylvania Pennsylvania]]></publisher-loc>
<publisher-name><![CDATA[Clinical and Laboratory Standard Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glupczynski]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Broutet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cantagrel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez Brea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2002</year>
<volume>21</volume>
<page-range>549-52</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sisto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maddalena]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Russello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonomi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dubini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial susceptibility testing of Helicobacter pylori determined by microdilution method using a new medium]]></article-title>
<source><![CDATA[Curr Microbiol]]></source>
<year>2009</year>
<volume>58</volume>
<page-range>559-63</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grignon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Glupczynski]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Husson]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Conroy]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori]]></article-title>
<source><![CDATA[Microb Drug Resist]]></source>
<year>2002</year>
<volume>8</volume>
<page-range>61-6</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[XD]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2000</year>
<volume>46</volume>
<page-range>121-3</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[López-Brea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of clarithromycin-resistant Helicobacter pylori in frozen gastric biopsies from pediatric patients by a commercially available fluorescent in situ hybridization]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2007</year>
<volume>59</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>421-3</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oleastro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Menard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lamouliatte]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barthelemy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2003</year>
<volume>41</volume>
<page-range>397-402</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres Debat]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Pérez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Olivares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Raisler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistence in straints isolated from patients in Uruguay]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2009</year>
<volume>101</volume>
<page-range>757-62</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fariña]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kasamatsu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Samudio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sanabria]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Laspina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial susceptibility of H. pylori straints obtained from Paraguayan patients]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2007</year>
<volume>135</volume>
<page-range>1009-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
